The Clorox Company (NYSE:CLX) Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its stake in The Clorox Company (NYSE:CLX - Free Report) by 756.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,047 shares of the company's stock after acquiring an additional 13,291 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Clorox were worth $2,216,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of CLX. HighPoint Advisor Group LLC boosted its holdings in Clorox by 7.6% in the 1st quarter. HighPoint Advisor Group LLC now owns 2,123 shares of the company's stock valued at $300,000 after purchasing an additional 150 shares during the last quarter. GW&K Investment Management LLC grew its stake in shares of Clorox by 239.1% in the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company's stock valued at $43,000 after buying an additional 208 shares during the period. Allianz Asset Management GmbH grew its stake in shares of Clorox by 33.3% in the 1st quarter. Allianz Asset Management GmbH now owns 23,007 shares of the company's stock valued at $3,388,000 after buying an additional 5,748 shares during the period. Gallacher Capital Management LLC purchased a new stake in shares of Clorox in the 1st quarter valued at approximately $436,000. Finally, Los Angeles Capital Management LLC grew its stake in shares of Clorox by 2.0% in the 1st quarter. Los Angeles Capital Management LLC now owns 218,021 shares of the company's stock valued at $32,104,000 after buying an additional 4,324 shares during the period. 78.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of Clorox stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the acquisition, the director directly owned 4,000 shares in the company, valued at $546,280. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.57% of the stock is currently owned by company insiders.

Clorox Stock Down 0.5%

Clorox stock traded down $0.62 during mid-day trading on Friday, reaching $130.80. 1,287,038 shares of the company's stock were exchanged, compared to its average volume of 1,776,629. The company has a market cap of $16.12 billion, a P/E ratio of 23.48, a P/E/G ratio of 3.44 and a beta of 0.51. The Clorox Company has a twelve month low of $117.35 and a twelve month high of $171.37. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07. The company has a fifty day moving average of $126.77 and a 200-day moving average of $140.15.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. Clorox's quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.71 earnings per share. Sell-side analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Analyst Upgrades and Downgrades

CLX has been the subject of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Clorox from $144.00 to $140.00 and set a "neutral" rating for the company in a research note on Friday. Wells Fargo & Company dropped their price target on shares of Clorox from $142.00 to $135.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 9th. Morgan Stanley dropped their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Barclays decreased their price objective on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating on the stock in a report on Tuesday, July 15th. Finally, Jefferies Financial Group decreased their price objective on shares of Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $144.83.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.